SYNOVO GMBH

Their core work

Synovo is a pharmaceutical SME based in Tübingen, Germany, specializing in drug discovery and medicinal chemistry with a strong focus on anti-inflammatory compounds and novel drug delivery mechanisms. Their work spans developing targeted nanodevices for autoimmune conditions like rheumatoid arthritis, designing antiviral drugs capable of crossing the blood-brain barrier, and exploring algae-derived bioactive compounds for inflammatory bowel disease. Across all their projects, the unifying thread is translating biological insights about inflammation and membrane barriers into therapeutic candidates.

What they specialise in

How they've shifted over time

Synovo's earliest H2020 work (FOLSMART, 2016) centered on nanotechnology-based drug delivery for autoimmune disease, a classical pharma approach using synthetic nanodevices. From 2019 onward, their focus shifted toward more complex biological challenges — crossing the blood-brain barrier with antivirals (NOVIRUSES2BRAIN) and harnessing natural algae-derived compounds for gut inflammation (Algae4IBD). The trajectory shows a clear move from synthetic delivery systems toward biologically-inspired and natural-source therapeutics, while maintaining their core interest in inflammation.

Synovo is pivoting from purely synthetic pharmaceutical approaches toward nature-derived therapeutics and microbiome-based treatments, suggesting future interest in bio-compound drug discovery for inflammatory and neurological conditions.

How they like to work

Synovo operates exclusively as a consortium participant, never leading projects, which is typical of a specialized SME contributing domain-specific medicinal chemistry expertise to larger research efforts. With 35 unique partners across just 3 projects, they join sizeable consortia (averaging ~12 partners per project) and appear comfortable working in diverse, multi-country teams. This profile suggests they are a reliable specialist contributor that larger consortia seek out for their pharmaceutical R&D capabilities.

Synovo has collaborated with 35 unique partners across 13 countries through their 3 H2020 projects, giving them a broad European network relative to their size. Their participation spans FET, NANO, and FOOD pillars, connecting them to partners in both fundamental research and applied food/health sectors.

What sets them apart

Synovo occupies a rare niche as a pharma SME that bridges synthetic medicinal chemistry with emerging natural-compound therapeutics, all centered on inflammation. Unlike larger pharmaceutical companies, they bring specialized agility to EU consortia — contributing focused drug design expertise without the overhead. Their combination of experience in nanodevice delivery, CNS barrier penetration, and algae-based bioactives makes them an unusually versatile partner for projects at the intersection of drug development and biological complexity.

Highlights from their portfolio

• NOVIRUSES2BRAIN
  Their largest funded project (EUR 548,000) tackling the ambitious goal of a single broad-spectrum antiviral drug that crosses the blood-brain barrier — a significant pharmacological challenge.
• Algae4IBD
  Represents their newest direction into algae-derived therapeutics for IBD, combining microbiome science with functional food — a growing field with strong commercial potential.
• FOLSMART
  Their first H2020 project, demonstrating early expertise in targeted nanodevice drug delivery for autoimmune conditions using folate-conjugated approaches.